WASHINGTON (AP) - The Food and Drug Administration on Friday approved Roche's injectable eye drug Lucentis for a new use in treating a diabetes-related condition that can cause blindness.
The agency cleared the drug for diabetic macular edema, a condition that causes swelling and blurred vision in patients with diabetes. In 2010, 3.9 million adults with diabetes reported vision problems, according to the FDA.
Lucentis is currently marketed for wet, age-related macular degeneration, the leading cause of blindness among the elderly. The drug has been facing new competition in that market from Regeneron Pharmaceutical's Eylea, which is cheaper and can be administered with fewer injections.
Side effects with Lucentis include bleeding around the tissue that lines the eyelids and increased pressure on the eyes.
Lucentis is manufactured by Roche's Genentech unit
Copyright 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
Friends and family of 20-year-old Ashley Nelson have not heard from her since September 17th.
All too often in WNY, cars slam into homes or businesses. But sometimes fixing the mess isn't as simple as cleaning up the broken glass and getting an insurance check for repairs.
The Niagara County SPCA is so packed with cats and dogs that the shelter is waiving adoption fees on many of its animals this holiday season. But a distraught pet owner came to us claiming the shelter sold her a cat that was so sick she …
Photos show two-story home Tuesday evening that left a family homeless.
Donald and Elaina Mead were both sentenced with six months in jail and five years probation.
The Town of Amherst is bringing in millions of dollars from court fines. Local drivers say it’s not rare to see flashing lights in the rearview mirror.